Identification of ISCA1 as novel immunological and prognostic biomarker for bladder cancer

被引:2
|
作者
Zhou, Renlong [1 ]
Peng, Naixiong [2 ]
Li, Wei [2 ]
机构
[1] Shenzhen Longhua Dist Cent Hosp, Dept Blood Transfus, Shenzhen, Peoples R China
[2] Shenzhen Longhua Dist Cent Hosp, Dept Urol, Shenzhen, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
pan-cancer; ISCA1; BLCA; GSEA; immune microenvironment; prognostic analysis; IMMUNE CHECKPOINT INHIBITORS; CELLS; CARCINOMA;
D O I
10.3389/fimmu.2022.975503
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundIron-sulfur cluster assembly 1 (ISCA1) has a significant effect on respiratory complexes and energy metabolism. Although there is some evidence that ISCA1 gene expression impacts energy metabolism and consequently has a role in tumorigenesis and cancer metastasis in different types of malignancies, no systematic pan-cancer study of the ISCA1 has been conducted. As a result, we sought to investigate ISCA1's predictive value in 33 cancer types as well as its possible immunological function. MethodsWe included the pan-cancer expression profile dataset and clinical data from the public database. Firstly, the single-sample Gene Set Enrichment Analysis (ssGSEa) approach was employed for analyzing the immune link in pan-cancer, while the limma package was utilized for analyzing the differential expression in cancer species. Subsequently, ciberport, MCP-counter, TIMER2, quanTIseq, and xCELL were employed for analyzing bladder cancer (BLCA)'s immune infiltration. Least absolute shrinkage and selection operator (Lasso) were employed for choosing the best gene to develop the immune risk scoring model. ResultsISCA1 gene expression was positively related to four immune signatures (chemokine, immunostimulator, MHC, and receptor) in BLCA. Samples of BLCA were sorted into two groups by the best cut-off of ISCA1 expression degree. The group with a high level of ISCA1 expression had a higher risk, suggesting that the ISCA1 gene was a risk factor in BLCA, and its high expression resulted in a poorer prognosis. Additionally, it was noted that ISCA1 was positively linked with these immune checkpoints. Moreover, there was a considerable positive link between ISCA1 and different immune properties in subgroups with different immune checkpoint inhibiting responses. Finally, an immune risk scoring model was made and it showed a better score in comparison to that of TIDE. ConclusionISCA1 can be a prognostic marker for a variety of cancers, particularly BLCA. Its high level of expression has a deleterious impact on the prognosis of BLCA patients. This strongly shows that ISCA1 is a significant prognostic factor for BLCA and that it could be used as a new prognostic detection target and treatment approach.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Multiple omics integrative analysis identifies GARS1 as a novel prognostic and immunological biomarker: from pan-cancer to bladder cancer (vol 14, 19025, 2024)
    Liu, Weihui
    Wei, Chengcheng
    He, Qingliu
    Chen, Zhaohui
    Zhuang, Wei
    Guo, Yihong
    Xue, Xueyi
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [22] Pan-cancer analysis of GJB5 as a novel prognostic and immunological biomarker
    Xiaojuan Yang
    Xunjie Cao
    Qing Zhu
    Hong Wu
    Scientific Reports, 15 (1)
  • [23] Identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer
    Di Wang
    Junye Liufu
    Qiyuan Yang
    Shengqun Dai
    Jiaqi Wang
    Biao Xie
    Biology Direct, 17
  • [24] Identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer
    Wang, Di
    Liufu, Junye
    Yang, Qiyuan
    Dai, Shengqun
    Wang, Jiaqi
    Xie, Biao
    BIOLOGY DIRECT, 2022, 17 (01)
  • [25] Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis
    Nedjadi, Taoufik
    Ahmed, Mohamed Eldigire
    Ansari, Hifzur R.
    Aouabdi, Sihem
    Al-Maghrabi, Jaudah
    CANCERS, 2023, 15 (23)
  • [26] Systematical analysis of ferroptosis regulators and identification of GCLM as a tumor promotor and immunological biomarker in bladder cancer
    Wang, Song
    Wang, He
    Zhu, Shaoxing
    Li, Fangyin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [27] Identification of CISD1 as a Prognostic Biomarker for Breast Cancer
    Liu, Xiao
    Cui, Qianqian
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2022, 15 : 8451 - 8465
  • [28] Comprehensive analysis of Transcription Factors identified novel prognostic biomarker in human bladder cancer
    Liao, Yihao
    Zou, Xuanxuan
    Wang, Keke
    Wang, Youzhi
    Wang, Miaomiao
    Guo, Tao
    Zhong, Boqiang
    Jiang, Ning
    JOURNAL OF CANCER, 2021, 12 (18): : 5605 - 5621
  • [29] Caveolin-1: a novel prognostic biomarker of radioresistance in cancer
    Mahmood, Javed
    Zaveri, Sarthak R.
    Murti, Stephanie C.
    Alexander, Allen A.
    Connors, Caroline Q.
    Shukla, Hem D.
    Vujaskovic, Zeljko
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2016, 92 (12) : 747 - 753
  • [30] Expanding the phenotype of mitochondrial disease: Novel pathogenic variant in ISCA1 leading to instability of the iron-sulfur cluster in the protein
    Lebigot, E.
    Hully, M.
    Amazit, L.
    Gaignard, P.
    Michel, T.
    Rio, M.
    Lombes, M.
    Therond, P.
    Boutron, A.
    Golinelli-Cohen, M. P.
    MITOCHONDRION, 2020, 52 : 75 - 82